These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis. Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137 [TBL] [Abstract][Full Text] [Related]
23. Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE. Das N; Biswas B; Khera R Adv Exp Med Biol; 2013; 735():55-81. PubMed ID: 23402019 [TBL] [Abstract][Full Text] [Related]
24. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. Becker-Merok A; Eilertsen GØ; Nossent JC J Rheumatol; 2010 Oct; 37(10):2039-45. PubMed ID: 20682675 [TBL] [Abstract][Full Text] [Related]
25. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371 [TBL] [Abstract][Full Text] [Related]
26. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus. Mahmoud RA; El-Gendi HI; Ahmed HH Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275 [TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Aringer M; Graninger WB; Steiner G; Smolen JS Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222 [TBL] [Abstract][Full Text] [Related]
28. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830 [TBL] [Abstract][Full Text] [Related]
29. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset. Dominguez-Gutierrez PR; Ceribelli A; Satoh M; Sobel ES; Reeves WH; Chan EK Arthritis Res Ther; 2014 Jan; 16(1):R23. PubMed ID: 24460726 [TBL] [Abstract][Full Text] [Related]
30. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Mok CC; Birmingham DJ; Ho LY; Hebert LA; Song H; Rovin BH Lupus; 2012 Jan; 21(1):36-42. PubMed ID: 21993384 [TBL] [Abstract][Full Text] [Related]
38. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies. Pradhan VD; Patwardhan MM; Ghosh K Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543 [TBL] [Abstract][Full Text] [Related]
39. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265 [TBL] [Abstract][Full Text] [Related]
40. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]